×
ABV-1703: a Immunostimulants Drug, Initially developed by American Brivision Corp., Now, its global highest R&D status is Phase 3, ...
Missing: url? | Show results with:url?
People also ask
This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of March totaling 93 drugs.
Missing: synergene/ q= bbef0fd2af5f4264a1c539a932071f36
Synapse is a global drug intelligence database for pharmaceutical companies, investment institutions and industrial parks. It provides complete and ...
Missing: synergene/ q= https:// bbef0fd2af5f4264a1c539a932071f36
Synapse is a global drug intelligence database for pharmaceutical companies, investment institutions and industrial parks. It provides complete and ...
Missing: synergene/ url? q= bbef0fd2af5f4264a1c539a932071f36
Synapse is a global drug intelligence database for pharmaceutical companies, investment institutions and industrial parks. It provides complete and ...
Missing: synergene/ q= bbef0fd2af5f4264a1c539a932071f36
Synapse Medicine helps healthcare providers and their patients optimize drug regimens along the entire care journey.
SGT-94: a RB1 modulators Drug, Initially developed by SynerGene Therapeutics, Inc., Now, its global highest R&D status is Pending, Mechanism: RB1 ...
VYN-201: a BET inhibitors Drug, Initially developed by Tay Therapeutics Ltd, Now, its global highest R&D status is Phase 1, Mechanism: BET ...
Missing: synergene/ bbef0fd2af5f4264a1c539a932071f36
In order to show you the most relevant results, we have omitted some entries very similar to the 8 already displayed. If you like, you can repeat the search with the omitted results included.